Filing Flows › Health Care › Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals (SNDX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Syndax Pharmaceuticals (SNDX) Q3 2026 earnings results →
Q3 2026 Revenue up 82% year over year to $83.3M · 59¢ of every $1 of revenue lost · operating margin -50.3%
Syndax Pharmaceuticals made $83.3M in Q3 2026 (+82% Y/Y): Product $60.7M, Collaboration Revenue $22.6M. Operating margin -50.3%, net loss $49.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $83.3M in Q3 2026, up 82% year over year and up 14% from the previous quarter. Product was the largest line at 73% of revenue. Product added $28.7M year over year (up 90%), 77% of the total change.
Operating costs exceeded revenue by $41.9M, an operating margin of -50.3%. Total costs grew 21% against revenue growth of 82%. The fastest-growing cost line was Other operating costs (+566%). The quarter ended with a net loss of $49.4M, wider than the previous quarter's $49.4M loss.
Operating cash flow was −$27.3M. Non-cash charges added back $6.0M of depreciation and $15.3M of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $83.3M | +82% | -50.3% | −$49.4M | −$27.3M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $72.8M | +92% | -54.9% | −$49.4M | −$30.3M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $64.9M | +224% | -52.7% | −$42.7M | −$50.3M |
| Q4 2025 | 10-K | Feb 26, 2026 | $68.7M | +795% | -91.0% | −$68.0M | −$69.5M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $45.9M | +267% | -125.2% | −$60.7M | −$70.5M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $38.0M | +984% | -182.7% | −$71.8M | −$87.8M |
| Q1 2025 | 10-Q | May 5, 2025 | $20.0M | — | -417.9% | −$84.8M | −$95.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn .
In its own words, from its 8-K, filed Aug 4, 2026.
Syndax Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +82% against the peers' median +10%. Operating margin: -50.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Q3 2026 | $83.3M | +82% | -50.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Syndax Pharmaceuticals 10-Q on SEC EDGAR · CIK 1395937 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns SNDX and who is buying
More on SNDX
- How Syndax Pharmaceuticals makes money: revenue by segment
- Syndax Pharmaceuticals next earnings date and what analysts expect
- Syndax Pharmaceuticals stock forecast, price target and fair value
- Who owns Syndax Pharmaceuticals stock: holders, funds and Congress trades
- Syndax Pharmaceuticals guidance and outlook
- Is Syndax Pharmaceuticals a takeover target? LBO and rumors
- Syndax Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results